Development of a Bispecific Antibody Targeting Clinical Isolates of Acinetobacter baumannii.

A humanized BsAb targeting distinct A. baumannii capsule moieties enabled potent and effective coverage of disparate A. baumannii clinical isolates. The BsAb enhances feasibility of development by minimizing the number of components of a promising novel therapeutic for these difficult-to-treat infections.